Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date β€” because we believe great analysis should be held accountable.

AllAAOIACADADMAAGIOALMSALMUALTSAPGEAUPHAVAVBCRXCAICAKECEGCELCCEPCGONCIENCNCCOGTCRCLCTRIGCTGOOGGPCRHALOHIMSHOODHWMIRENIVVDKALAKALVLENZLEVILITELRMRLULULUNRMDGLMESOMOHMTCHMUMVSTNBISNKENRIXNVAXOKUROLMAONCOSCRPHATPLRXPYGRBLXRDDTRIGLRKLBSGHCSPRYSRPTTARSTBPHTHTRVITSHAUNHVEONVORWVEXFORZLAB
CG Oncology is a clinical-stage biopharmaceutical company focused on developing cretostimogene grenadenorepvec, an intravesical oncolytic immunotherapy for non-muscle invasive bladder cancer (NMIBC). Its pivotal Phase 3 BOND-003 trial demonstrated strong efficacy with a 75.5% complete response rate and unprecedented durability (median duration of response >28 months), alongside an excellent safety profile featuring no Grade 3+ treatment-related adverse events. The drug holds a competitive edge due to its local administration, independence from BCG supply, and superior risk-benefit profile compared to systemic alternatives like Keytruda. With a robust cash position of $661.1 million extending into H1 2028, the company is well-funded to pursue regulatory approval and commercial launch. Despite inherent clinical-stage risks, analysts view CGON as a speculative buy given its multi-billion-dollar market opportunity and compelling clinical data

An In-Depth Investment Analysis of CG Oncology (CGON): Assessing a Potential New Standard of Care in Non-Muscle Invasive Bladder Cancer

2025-09-10Change from report: +101.3%1M: +28.6%3M: +24.1%

CG Oncology is a clinical-stage biopharmaceutical company focused on developing cretostimogene grenadenorepvec, an intravesical oncolytic immunotherapy for non-muscle invasive bladder cancer (NMIBC). Its pivotal Phase 3 BOND-003 trial demonstrated strong efficacy with a 75.5% complete response rate and unprecedented durability (median duration of response >28 months), alongside an excellent safety profile featuring no Grade 3+ treatment-related adverse events. The drug holds a competitive edge due to its local administration, independence from BCG supply, and superior risk-benefit profile compared to systemic alternatives like Keytruda. With a robust cash position of $661.1 million extending into H1 2028, the company is well-funded to pursue regulatory approval and commercial launch. Despite inherent clinical-stage risks, analysts view CGON as a speculative buy given its multi-billion-dollar market opportunity and compelling clinical data